Author

María José Casanova

EFFECTIVENESS AND SAFETY OF VEDOLIZUMAB AND USTEKINUMAB THERAPY FOR COMPLEX PERIANAL FISTULA IN CROHN’S DISEASE: THE HEAL STUDY
EFFECTIVENESS AND SAFETY OF VEDOLIZUMAB AND USTEKINUMAB THERAPY FOR COMPLEX PERIANAL FISTULA IN CROHN’S DISEASE: THE HEAL STUDY

EFFECTIVENESS AND SAFETY OF SWITCHING FROM ADALIMUMAB REFERENCE TO BIOSIMILAR IN PATIENTS WITH INFLAMMATORY BOWEL DISEASE: THE ADA-SWITCH STUDY
EFFECTIVENESS AND SAFETY OF SWITCHING FROM ADALIMUMAB REFERENCE TO BIOSIMILAR IN PATIENTS WITH INFLAMMATORY BOWEL DISEASE: THE ADA-SWITCH STUDY

María José Casanova  et al.

EFFECTIVENESS AND SAFETY OF VEDOLIZUMAB AND USTEKINUMAB THERAPY FOR COMPLEX PERIANAL FISTULA IN CROHN’S DISEASE: THE HEAL STUDY
EFFECTIVENESS AND SAFETY OF VEDOLIZUMAB AND USTEKINUMAB THERAPY FOR COMPLEX PERIANAL FISTULA IN CROHN’S DISEASE: THE HEAL STUDY

María José Casanova  et al.

EFFECTIVENESS AND SAFETY OF SWITCHING FROM ADALIMUMAB REFERENCE TO BIOSIMILAR IN PATIENTS WITH INFLAMMATORY BOWEL DISEASE: THE ADA-SWITCH STUDY
EFFECTIVENESS AND SAFETY OF SWITCHING FROM ADALIMUMAB REFERENCE TO BIOSIMILAR IN PATIENTS WITH INFLAMMATORY BOWEL DISEASE: THE ADA-SWITCH STUDY

LONG-TERM EVOLUTION AFTER ANTI-TNF DRUG DISCONTINUATION IN PATIENTS WITH INFLAMMATORY BOWEL DISEASE
LONG-TERM EVOLUTION AFTER ANTI-TNF DRUG DISCONTINUATION IN PATIENTS WITH INFLAMMATORY BOWEL DISEASE

María José Casanova  et al.

Current concepts on microscopic colitis: evidence-based statements and recommendations of the Spanish Microscopic Colitis Group
Current concepts on microscopic colitis: evidence-based statements and recommendations of the Spanish Microscopic Colitis Group

María José Casanova  et al.

RISK FACTORS AND LONG-TERM OUTCOMES ASSOCIATED WITH IMMUNOSUPPRESSION IN PATIENTS WITH ULCERATIVE PROCTITIS: RESULTS FROM THE ENEIDA REGISTRY
RISK FACTORS AND LONG-TERM OUTCOMES ASSOCIATED WITH IMMUNOSUPPRESSION IN PATIENTS WITH ULCERATIVE PROCTITIS: RESULTS FROM THE ENEIDA REGISTRY

María José Casanova  et al.

LONG-TERM OUTCOMES OF BIOLOGIC THERAPY IN CROHN’S DISEASE COMPLICATED WITH INTERNAL FISTULIZING DISEASE: BIOSCOPE STUDY FROM GETECCU
LONG-TERM OUTCOMES OF BIOLOGIC THERAPY IN CROHN’S DISEASE COMPLICATED WITH INTERNAL FISTULIZING DISEASE: BIOSCOPE STUDY FROM GETECCU

María José Casanova  et al.

EFFECTIVENESS AND SAFETY OF USTEKINUMAB IN ULCERATIVE COLITIS: REAL WORLD EVIDENCE FROM ENEIDA REGISTRY
EFFECTIVENESS AND SAFETY OF USTEKINUMAB IN ULCERATIVE COLITIS: REAL WORLD EVIDENCE FROM ENEIDA REGISTRY

María José Casanova  et al.

EFFECTS OF ANTI-TNF-ALPHA AND ANTI-ALPHA4BETA7 DRUGS ON CIRCULATING DENDRITIC CELLS MIGRATORY CAPACITY IN INFLAMMATORY BOWEL DISEASE
EFFECTS OF ANTI-TNF-ALPHA AND ANTI-ALPHA4BETA7 DRUGS ON CIRCULATING DENDRITIC CELLS MIGRATORY CAPACITY IN INFLAMMATORY BOWEL DISEASE

María José Casanova  et al.

INCIDENCE AND RISK FACTORS ASSOCIATED WITH RECURRENCE OF CROHN´S DISEASE AFTER DEFINITIVE PANPROCTOCOLECTOMY AND ILEOSTOMY: THE IFARPI STUDY
INCIDENCE AND RISK FACTORS ASSOCIATED WITH RECURRENCE OF CROHN´S DISEASE AFTER DEFINITIVE PANPROCTOCOLECTOMY AND ILEOSTOMY: THE IFARPI STUDY

María José Casanova  et al.

BENEFITS OF PAEDIATRIC TO ADULT TRANSITION PROGRAM IN INFLAMMATORY BOWEL DISEASE: THE BUTTERFLY STUDY OF GETECCU
BENEFITS OF PAEDIATRIC TO ADULT TRANSITION PROGRAM IN INFLAMMATORY BOWEL DISEASE: THE BUTTERFLY STUDY OF GETECCU

María José Casanova  et al.

TOFACITINIB IN ULCERATIVE COLITIS: REAL WORLD EVIDENCE FROM ENEIDA REGISTRY
TOFACITINIB IN ULCERATIVE COLITIS: REAL WORLD EVIDENCE FROM ENEIDA REGISTRY

María José Casanova  et al.

EFFECTIVENESS AND SAFETY OF A SECOND-LINE RESCUE THERAPY IN HOSPITALISED PATIENTS WITH ACUTE SEVERE ULCERATIVE COLITIS STEROID-REFRACTORY AFTER FAILING INFLIXIMAB OR CICLOSPORIN (REASUC STUDY)
EFFECTIVENESS AND SAFETY OF A SECOND-LINE RESCUE THERAPY IN HOSPITALISED PATIENTS WITH ACUTE SEVERE ULCERATIVE COLITIS STEROID-REFRACTORY AFTER FAILING INFLIXIMAB OR CICLOSPORIN (REASUC STUDY)

María José Casanova  et al.

EX VIVO EFFECTS OF INFLIXIMAB ON THE LONG NON-CODING RNAS EXPRESSION LEVELS IN CROHN´S DISEASE
EX VIVO EFFECTS OF INFLIXIMAB ON THE LONG NON-CODING RNAS EXPRESSION LEVELS IN CROHN´S DISEASE

María José Casanova  et al.

LONG-TERM TRENDS IN TARGETED THERAPIES USAGE IN INFLAMMATORY BOWEL DISEASE: TRENDY STUDY OF ENEIDA
LONG-TERM TRENDS IN TARGETED THERAPIES USAGE IN INFLAMMATORY BOWEL DISEASE: TRENDY STUDY OF ENEIDA

María José Casanova  et al.

MICROBIOME CHARACTERIZATION IN STOOL FROM NEWLY DIAGNOSED PATIENTS WITH INFLAMMATORY BOWEL DISEASE
MICROBIOME CHARACTERIZATION IN STOOL FROM NEWLY DIAGNOSED PATIENTS WITH INFLAMMATORY BOWEL DISEASE

María José Casanova  et al.

SAFETY OF INFLAMMATORY BOWEL DISEASE DRUGS DURING PREGNANCY AND BREASTFEEDING: MOTHERS AND BABIES' OUTCOMES (DUMBO REGISTRY)
SAFETY OF INFLAMMATORY BOWEL DISEASE DRUGS DURING PREGNANCY AND BREASTFEEDING: MOTHERS AND BABIES' OUTCOMES (DUMBO REGISTRY)

María José Casanova  et al.

URINARY METABOLOME IN NEWLY DIAGNOSED TREATMENT-NAÏVE CROHN’S DISEASE PATIENTS: RESULTS FROM THE IBDOMICS STUDY
URINARY METABOLOME IN NEWLY DIAGNOSED TREATMENT-NAÏVE CROHN’S DISEASE PATIENTS: RESULTS FROM THE IBDOMICS STUDY

María José Casanova  et al.

PROTEOMIC PROFILE OF SERUM AND URINE IN NEWLY DIAGNOSED PATIENTS WITH INFLAMMATORY BOWEL DISEASE: NEW APPROACH FOR BIOMARKER DISCOVERY
PROTEOMIC PROFILE OF SERUM AND URINE IN NEWLY DIAGNOSED PATIENTS WITH INFLAMMATORY BOWEL DISEASE: NEW APPROACH FOR BIOMARKER DISCOVERY

María José Casanova  et al.

Item 1 - 20 / 29
1
2